Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.
One hundred sixty-five patients were randomized to receive either interferon alfa-n1 (Wellferon; Burroughs Wellcome Co, Research Triangle Park, NC) alone or with vinblastine. An initial six-cycle induction treatment consisted of interferon given at daily doses of 3, 5, 20, 20, and 20 x 10(6) U/m2 every 2 weeks. Vinblastine at a dose of 10 mg/m2 (later decreased to 5 mg/m2) was given on day 1 of alternate cycles. Toxicities were generally well tolerated. The overall response rate was 10% with no significant difference between treatment arms. Survival was also not significantly different for the arms. A small subset of patients (16) with metastases only to the lungs had a high complete response (CR) and partial response (PR) rate of 44%. Responses were durable, and overall survival of this group was much better than that of the other patients.
Neidhart
J A
JA
University of New Mexico, Albuquerque.
Anderson
S A
SA
Harris
J E
JE
Rinehart
J J
JJ
Laszlo
J
J
Dexeus
F H
FH
Einhorn
L H
LH
Trump
D L
DL
Benedetto
P W
PW
Tuttle
R L
RL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy; D008297:Male; D012074:Remission Induction; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage
D007370:Interferon Type I; D014747:Vinblastine